The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | The patient population that may benefit most from Type II JAK inhibition
In this video, Andrew Dunbar, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses which patient population may benefit most from Type II JAK inhibition. Dr Dunbar highlights that the goal is for Type II JAK inhibitors to replace currently approved inhibitors for the treatment of relapsed/refractory (R/R) myelofibrosis (MF), with the potential to move these novel agents into the frontline setting if data demonstrate their efficacy. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So currently, as of now, we think that the patient population that will benefit most are those individuals with myelofibrosis who have been receiving a clinically approved JAK inhibitor for some time, but are now showing increasing signs of loss of response. So maybe their spleens are getting bigger, maybe their symptoms are worsening, maybe their white counts are going up...
So currently, as of now, we think that the patient population that will benefit most are those individuals with myelofibrosis who have been receiving a clinically approved JAK inhibitor for some time, but are now showing increasing signs of loss of response. So maybe their spleens are getting bigger, maybe their symptoms are worsening, maybe their white counts are going up. And so the goal of the Type II inhibitor is that these agents will replace these current inhibitors with the goal of seeing, again, can we further maximize treatment response or prolong treatment response, but maybe even best-case scenario, see these MPN cells go away or at least be reduced in the bone marrow of these treated patients. And then long-term, I think we’ll have to see, you know, if there is a response in this relapsed/refractory setting, whether or not there might be a role for these Type II inhibitors for patients who are newly diagnosed in an upfront setting. And so again, this will all sort of be borne out based on the results of this ongoing trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Ajax Therapeutics.
